Clinical Trials Browser

Phase 2 × Liver Diseases × aumolertinib × Clear all

NCT05662813 2022-12-23

Almonertinib Therapy in Patients With Abnormal Liver Function After EGFR-TKI Treatment, or Almonertinib First-line Therapy in Patients With Basic Hepatopathy

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung, Digestive System Diseases, Liver Diseases